Within the world of Big Pharma, Roche (NASDAQOTH: RHHBY )
offers a pretty compelling mix. Not only does Roche have one of the
strongest oncology platforms today, it also offers one of the deepest
pipelines. The company's non-oncology pipeline is not as strong in
volume, but could well make up for that in quality if a couple of
high-risk trials go the right way. Roche's modest debt and large cash
generation capability also raises the prospect of M&A as biotech
valuations quickly become more reasonable.
Read the full article here:
This Forgotten Pharma Could Be a Hit for Your Portfolio
No comments:
Post a Comment